Reishi Bioactive Compounds: Triterpenes, Polysaccharides

Reishi (Ganoderma lucidum)

400+ bioactive compounds

A comprehensive 2006 survey of Ganoderma lucidum catalogued over 400 distinct bioactive compounds across triterpenes, polysaccharides, proteins, alkaloids, and sterols, making reishi one of the most chemically complex medicinal fungi studied.

Paterson, Phytochemistry, 2006

120+

distinct triterpenes identified in G. lucidum

23 studies

analyzed in the 2026 triterpene anti-inflammatory meta-analysis

5 of 19

US commercial supplements matched their label claims in a 2017 analysis

Paterson, Phytochemistry, 2006

View as image ↗

Reishi mushroom contains more than 400 distinct bioactive compounds. That figure comes from a 2006 comprehensive survey of Ganoderma lucidum by Paterson, published in Phytochemistry. It points to the first thing worth understanding about reishi: this is not a single-ingredient extract the way aspirin is derived from willow bark.^[1] It is a chemistry library organized into three major classes that work through entirely different biological pathways. Understanding those classes, how they differ, and what pulls each one out of the mushroom explains why two reishi supplements sitting side by side on a shelf can be fundamentally different products.

For the broader context on reishi's traditional history and health applications, see What Is Reishi Mushroom? The Science Behind the "Mushroom of Immortality". This article goes one level deeper into the chemistry.

Three Reishi Mushroom Bioactive Compound Classes, Three Different Targets

Reishi's bioactive profile organizes into three primary classes. They're worth distinguishing early because they reach the body through different mechanisms and require different extraction methods to capture.^[2]

A 2025 pharmacology review by Sarkar et al. in Natural Product Research maps this architecture clearly: polysaccharides handle immune activation, triterpenes drive anti-inflammatory and liver-protective effects, and sterols modulate cholesterol processing through mechanisms similar to plant phytosterols.^[3] The practical implication is that the solubility difference between polysaccharides and triterpenes creates an extraction problem. A product extracted with only hot water captures polysaccharides but loses triterpenes. A product extracted with only ethanol captures triterpenes but loses polysaccharides. Most supplements use one or the other.

Sterols deserve an early note. Ergosterol is the primary sterol in most mushrooms, and in the body it converts to vitamin D2 under UV exposure. In reishi specifically, ergosterol appears in both the fruiting body and in spore oil. The research on sterols is real but considerably thinner than the triterpene and polysaccharide literature, so they get proportionally less space below.

Triterpenes: 120+ Bitter Compounds That Suppress the Inflammatory Switch

Reishi produces more than 120 distinct triterpenes, almost all built on the same lanostane carbon backbone.^[2] The best-studied group is the ganoderic acids, particularly ganoderic acids A, B, C, D, and T. They are responsible for reishi's unmistakably bitter taste, and in crude preparations bitterness functions as a rough proxy for triterpene presence.

The cell target they work through is a protein complex called NF-κB, which acts as an amplifier for the body's inflammatory response. When cells detect stress, infection, or injury, NF-κB turns on production of inflammatory proteins including COX-2, TNF-α, and a family of signaling molecules called interleukins. Dudhgaonkar et al. (2009) isolated specific triterpenes from G. lucidum and showed they suppress both NF-κB and a related pathway called AP-1, which together reduced COX-2 expression in cell experiments.^[4] The ganoderic acids were the active agents, not the whole extract.

The most rigorous synthesis of the triterpene evidence came out in 2026. Pozzobon et al. published a systematic review and meta-analysis covering 23 preclinical studies from 2003 to 2025.^[5] Their findings are specific: G. lucidum triterpenes significantly reduce three key inflammatory signaling molecules, TNF-α, IL-1β, and IL-6, through downregulation of the MAPK and TLR-4/NF-κB pathways. This is the most comprehensive synthesis of triterpene mechanisms published to date, and it appears nowhere in consumer-facing content.

For a deeper look at individual ganoderic acid compounds and their specific research profiles, see Ganoderic Acids: The Unique Triterpenes in Reishi.

What a Single Triterpene Can Do: Ganoderic Acid A and Amyloid Clearance

Research on individual ganoderic acids illustrates something important about how to think about this compound class. The 120+ triterpenes are not interchangeable variants doing the same thing at different potencies. Individual compounds have specific targets.

Qi et al. (2021) isolated ganoderic acid A specifically and tested it against amyloid-beta protein, the misfolded protein that accumulates in Alzheimer's disease, in both cell cultures and a mouse model of the disease.^[6] Ganoderic acid A promoted clearance of amyloid-beta through a cellular cleanup process called autophagy, operating through a protein called Axl. In the mice, this produced measurable improvement in cognitive function tests.

This is preclinical work, and the gap between a mouse model and a human treatment is long. But the study demonstrates why whole-extract research showing broad effects likely reflects the combined contributions of many individual compounds, each hitting a distinct target. The anti-inflammatory effects described in the Pozzobon meta-analysis probably represent dozens of ganoderic acids working in parallel, not one active molecule driving everything.

Polysaccharides: The Water-Soluble Half That Activates Immune Cells

The polysaccharide fraction of reishi differs from the triterpenes in nearly every chemical property. Triterpenes are fat-soluble, concentrated in cell walls, and bitter. Polysaccharides are water-soluble, distributed throughout the mushroom flesh, and tasteless.

The structural backbone of reishi's immune-active polysaccharides is a molecule called β-1,3-D-glucan. Dong et al. (2012) isolated and characterized a novel water-soluble version of this glucan from G. lucidum spores, confirming its β-1,3-D-glucopyranose backbone structure and demonstrating immune-stimulating activity in cell experiments.^[7] The shape of the molecule matters here because it determines how immune cells recognize it.

That recognition runs through a receptor called TLR-4, a protein on the surface of immune cells called macrophages. When a beta-glucan binds TLR-4, it triggers the macrophage to produce cytokines, which are signaling proteins that in turn activate T cells, B cells, and natural killer cells. This is the core immune-activating mechanism.

Cai et al. (2017) tested G. lucidum polysaccharides in a mouse model of brain inflammation, specifically looking at microglial cells, which function as the brain's version of macrophages.^[8] The polysaccharides reduced microglial inflammatory activity and improved behavioral outcomes in the mice. This establishes a brain-accessible pathway for polysaccharides that is separate from anything the triterpene fraction does.

The Gut Microbiome Pathway Nobody Mentions

Most discussions of reishi's immune effects focus on direct immune cell activation. But polysaccharides also reach the colon largely undigested, where they serve as food for specific bacterial populations.

Guo et al. (2021) gave G. lucidum polysaccharides to mice with colon inflammation and tracked both microbiome composition and inflammatory markers simultaneously.^[9] The polysaccharides increased populations of Lactobacillus, a beneficial bacterial genus, and decreased Fusobacterium, which is associated with gut inflammation. Colon inflammatory markers fell at the same time. Some of the anti-inflammatory effect appeared to operate through the microbiome shift itself rather than through direct immune cell contact.

This gut pathway is absent from virtually every consumer discussion of reishi. It also has a timing implication: shifting microbial populations takes longer than triggering a cytokine response, which is consistent with human reports that reishi effects take weeks rather than days to become apparent.

For a detailed look at how triterpene and polysaccharide pathways connect to reishi's broader pharmacological picture, see The Pharmacology of Ganoderma lucidum: How Reishi Works.

Reishi Spores: More Concentrated, but With a Bioavailability Problem

Reishi spores are the reproductive cells released from the pores on the underside of mature caps. They're roughly 8 to 10 micrometers across and coated in a hard outer shell called the sporoderm. That shell is both an asset and a problem.

Soccol et al. (2016) reviewed the compound profile of G. lucidum spores specifically and found them notably richer in certain triterpenes and sterols than the fruiting body flesh.^[10] Spores also contain significant amounts of spore oil, which is composed mainly of ergosterol and fatty acids. On paper, this makes spore-based preparations an attractive high-concentration source.

Wang et al. (2017) demonstrated the problem: the intact sporoderm dramatically limits how much of the interior compounds actually gets absorbed.^[11] Using a combination of chemical and physical methods to break the spore wall, they showed that compound release increased substantially once the shell was opened. This is the scientific basis for "cracked spore" or "broken-sporoderm" products, which mechanically open the shell before processing.

A 2023 systematic review by Thuy et al. in Cureus evaluated the pharmacological activity and safety of spore preparations specifically.^[12] The review found antitumor, liver-protective, and immune-modulating activity across studied preparations, with generally favorable safety profiles, though rare hepatotoxicity cases appeared in the reviewed literature. The authors support spore preparations as pharmacologically active, with the caveat that intact spores require sporoderm processing to deliver their compound content.

For the broader comparison of compound profiles between fruiting body and mycelium-based products, see Do Fruiting Bodies Have More Bioactive Compounds Than Mycelium?.

Why Two Solvents Capture More Compounds Than One

The solubility difference between polysaccharides and triterpenes creates a straightforward problem for product manufacturing: no single solvent captures both.

Zheng et al. (2020) optimized extraction conditions for both fractions using ultrasonic-assisted extraction and found exactly what the chemistry predicts.^[13] Polysaccharides extracted most efficiently in hot water. Triterpenoids extracted most efficiently in ethanol. Neither single-solvent method captured the complete bioactive profile of the mushroom.

This is the mechanistic basis for dual extraction, a process that runs hot water and ethanol extractions separately, then combines both concentrates. A hot-water-only product, including most mushroom teas and many powders, captures polysaccharides but loses the triterpene fraction entirely. An ethanol-only product, common in certain tinctures, captures triterpenes and loses polysaccharides.

For a detailed look at how dual extraction works in practice and what to look for on a product label, see Double-Extraction Mushroom Tinctures: Why Alcohol + Water Captures More Compounds.

Commercial Reishi Supplements: Only 5 of 19 Matched Their Label Claims

The gap between theoretical compound content and what's actually in a bottle is substantial.

Wu et al. (2017) analyzed 19 batches of commercial G. lucidum dietary supplements sold in the United States for both triterpene and polysaccharide content.^[14] The measured ingredients of only 5 products (26.3%) actually matched their label claims. Triterpenes characteristic of authentic G. lucidum were detectable in just 8 of the 19 products (42.1%) by HPTLC fingerprinting, and the immune-active branched 1,3-β-D-glucan was found in only 5 of 19 (26.3%). The implication is significant: a product with undetectable G. lucidum triterpenes is, by the mechanism described above, delivering no NF-κB/MAPK anti-inflammatory activity at any dose.

The Quality Gap

How Many of 19 US Reishi Supplements Actually Delivered

Wu et al. (2017) chemically tested 19 batches of commercial Ganoderma lucidum supplements sold in the United States. Each bar shows how many of those 19 products cleared the bar — the denominator stays fixed so the shortfall is visible at a glance.

Contained G. lucidum triterpenes

8 of 19 · 42.1%

Detectable by HPTLC fingerprinting (the NF-κB / MAPK actives)

Contained immune-active 1,3-β-D-glucan

5 of 19 · 26.3%

The branched glucan behind reishi’s immune activity

Matched their label claims

5 of 19 · 26.3%

Measured ingredients in accordance with the label

Fewer than half the products contained detectable G. lucidum triterpenes, and roughly three in four did not match their own label. Compound verification — not just the species name — is the real prerequisite for a reishi purchase.

Source: Wu et al. (2017), Scientific Reports 7:7792 [ref 14].

McCleary and Draga (2016) approached the measurement problem from a different angle.^[15] They developed and validated standardized methods for measuring beta-glucan in mushroom products and found meaningful variation in values coming from the testing methodology itself, not just from product differences. This means beta-glucan claims on supplement labels are unreliable not only because products vary, but because there is no universal measurement standard enforced across the industry.

The 2025 review by Ren et al. in Food Science & Nutrition provides the most current compound catalogue as a reference point: β-1,3-D-glucan polysaccharides, 120+ lanostane triterpenes, ergosterol and related sterols, plus minor compounds including proteins and alkaloids.^[2] Any supplement claiming to deliver the benefits associated with the reishi literature should be able to demonstrate standardized levels of at least the triterpene and beta-glucan fractions, with third-party testing documentation. Most cannot.

Species mislabeling compounds this further: Wu's 2017 analysis covered products labeled G. lucidum, but as detailed in Ganoderma lucidum Taxonomy: How to Identify Authentic Reishi, the majority of those products likely contain a related but taxonomically distinct species, G. sichuanense or G. lingzhi, which may carry a somewhat different compound profile.

The Bottom Line

Reishi's bioactive chemistry falls into three distinct classes with distinct mechanisms: triterpenes, led by the ganoderic acids, suppress inflammation through NF-κB and MAPK pathway downregulation; polysaccharides activate immune cells via TLR-4 receptors and modulate the gut microbiome; and sterols, primarily ergosterol, support cholesterol metabolism and membrane function. Capturing all three requires dual extraction using both hot water and ethanol. The quality gap in commercial products is severe: in a 2017 analysis of 19 US supplements, only 5 (26.3%) matched their label claims and G. lucidum triterpenes were detectable in just 8 of them, making compound verification, not just species identification, the prerequisite for evaluating any reishi preparation.

Frequently Asked Questions

What are the main bioactive compounds in reishi mushroom?

Reishi contains three primary compound classes: triterpenes (120+ individual compounds, including ganoderic acids A, B, C, D), polysaccharides (primarily β-1,3-D-glucan), and sterols (primarily ergosterol). A 2006 comprehensive survey by Paterson catalogued over 400 distinct bioactive compounds in G. lucidum across these and minor classes including proteins and alkaloids. The triterpene and polysaccharide fractions carry the majority of the published pharmacological research.

What are ganoderic acids and what do they do?

Ganoderic acids are a class of triterpene compounds found almost exclusively in Ganoderma species. More than 120 have been identified in reishi, all built on a lanostane carbon backbone. They work by suppressing two cellular signaling pathways that amplify inflammation: NF-κB, which controls inflammatory protein production, and MAPK, which amplifies the stress response. A 2026 meta-analysis of 23 preclinical studies by Pozzobon et al. confirmed they significantly reduce TNF-α, IL-1β, and IL-6 through those pathways.

What is the difference between reishi triterpenes and polysaccharides?

Triterpenes and polysaccharides are chemically distinct and operate through entirely different mechanisms. Triterpenes are fat-soluble and reduce inflammation by suppressing NF-κB and MAPK signaling pathways. Polysaccharides are water-soluble and activate immune cells by binding TLR-4 receptors; they also act as prebiotics that shift gut microbiome composition. Because they dissolve in different solvents, a hot-water extraction captures polysaccharides but misses triterpenes, and an ethanol extraction does the reverse.

How much beta-glucan does reishi mushroom contain?

Beta-glucan content in commercial reishi products varies significantly. A 2017 analysis by Wu et al. of 19 US commercial reishi supplements found the immune-active branched 1,3-β-D-glucan was detectable in only 5 of them (26.3%). McCleary and Draga (2016) also found that the testing methodology itself introduces variation, meaning label claims for beta-glucan are unreliable without a standardized Certificate of Analysis from a third-party lab.

Are reishi mushroom supplements standardized for active compounds?

Most are not standardized in any meaningful way. The 2017 analysis by Wu et al. of 19 US reishi products found only 5 (26.3%) matched their label claims, with G. lucidum triterpenes detectable in just 8 (42.1%). Legitimate standardization specifies both beta-glucan percentage and triterpene percentage with supporting third-party testing documentation. The majority of consumer products specify neither.

What is the difference between reishi fruiting body and mycelium compounds?

The fruiting body contains the highest concentrations of both triterpenes and beta-glucan polysaccharides in mature form. Mycelium contains polysaccharides but typically lower triterpene concentrations. Spores are the most concentrated source of triterpenes and sterols but require sporoderm-breaking processing to make those compounds available, because intact spore walls block absorption. The 2023 systematic review by Thuy et al. specifically examines the pharmacological profile of spore preparations.

Do reishi supplements actually contain the compounds they claim?

Based on published testing data, many do not. Wu et al. (2017) found that only 5 of 19 US products (26.3%) matched their label claims, with G. lucidum triterpenes detectable in just 8 (42.1%). McCleary and Draga (2016) found that beta-glucan measurement methodology is inconsistently applied across the industry. Species mislabeling adds a third layer of uncertainty: products labeled G. lucidum frequently contain a related but different species. A Certificate of Analysis with third-party-verified beta-glucan and triterpene levels is the only reliable check.

Sources & References

1. 1RTHM-00107·Paterson, R Russell M (2006). “Ganoderma - a therapeutic fungal biofactory..” Phytochemistry.Study breakdown →PubMed →↩
2. 2RTHM-02166·Ren, Sizhu et al. (2025). “A Review of Bioactive Components and Pharmacological Effects of Ganoderma lucidum..” Food science & nutrition.Study breakdown →PubMed →↩
3. 3RTHM-02175·Sarkar, Tumpa et al. (2025). “Reishi Mushroom (Ganoderma lucidum): pharmacology of a potent healer in traditional Chinese medicine..” Natural product research.Study breakdown →PubMed →↩
4. 4RTHM-00152·Dudhgaonkar, Shailesh et al. (2009). “Suppression of the inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum..” International immunopharmacology.Study breakdown →PubMed →↩
5. 5RTHM-02241·Pozzobon, Rafaela Guedes et al. (2026). “Anti-Inflammatory Potential of Ganoderma lucidum Triterpenes: A Systematic Review and Meta-Analysis of Preclinical Evidence..” Pharmaceuticals (Basel.Study breakdown →PubMed →↩
6. 6RTHM-00712·Qi, Li-Feng-Rong et al. (2021). “Ganoderic Acid A Promotes Amyloid-β Clearance (In Vitro) and Ameliorates Cognitive Deficiency in Alzheimer's Disease (Mouse Model) through Autophagy Induced by Activating Axl..” International journal of molecular sciences.Study breakdown →PubMed →↩
7. 7RTHM-00248·Dong, Qun et al. (2012). “A novel water-soluble β-D-glucan isolated from the spores of Ganoderma lucidum..” Carbohydrate research.Study breakdown →PubMed →↩
8. 8RTHM-00462·Cai, Qing et al. (2017). “Polysaccharides from Ganoderma lucidum attenuate microglia-mediated neuroinflammation and modulate microglial phagocytosis and behavioural response..” Journal of neuroinflammation.Study breakdown →PubMed →↩
9. 9RTHM-00690·Guo, Cuiling et al. (2021). “Ganoderma lucidum polysaccharide modulates gut microbiota and immune cell function to inhibit inflammation and tumorigenesis in colon..” Carbohydrate polymers.Study breakdown →PubMed →↩
10. 10RTHM-00448·Soccol, Carlos Ricardo et al. (2016). “Pharmacological Properties of Biocompounds from Spores of the Lingzhi or Reishi Medicinal Mushroom Ganoderma lucidum (Agaricomycetes): A Review..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
11. 11RTHM-00496·Wang, Jiajia et al. (2017). “Breaking the sporoderm of Ganoderma lucidum spores by combining chemical reaction with physical actuation..” Natural product research.Study breakdown →PubMed →↩
12. 12RTHM-01802·Thuy, Nguyen Huu Lac et al. (2023). “Pharmacological Activities and Safety of Ganoderma lucidum Spores: A Systematic Review..” Cureus.Study breakdown →PubMed →↩
13. 13RTHM-00668·Zheng, Shizhong et al. (2020). “Optimization of ultrasonic-assisted extraction of polysaccharides and triterpenoids from the medicinal mushroom Ganoderma lucidum and evaluation of their in vitro antioxidant capacities..” PloS one.Study breakdown →PubMed →↩
14. 14RTHM-00499·Wu, Ding-Tao et al. (2017). “Evaluation on quality consistency of Ganoderma lucidum dietary supplements collected in the United States..” Scientific reports.Study breakdown →PubMed →↩
15. 15RTHM-00438·McCleary, Barry V et al. (2016). “Measurement of β-Glucan in Mushrooms and Mycelial Products..” Journal of AOAC International.Study breakdown →PubMed →↩